The Src homology (SH)2 domain-containing proteintyrosine phosphatase SHP-1 is tyrosine phosphorylated in platelets in response to the glycoprotein VI (GPVI)-selective agonist collagen-related peptide (CRP), collagen, and thrombin. Two major unidentified tyrosinephosphorylated bands of 28 and 32 kDa and a minor band of 130 kDa coprecipitate with SHP-1 in response to all three agonists. Additionally, tyrosine-phosphorylated proteins of 50 -55 and 70 kDa specifically associate with SHP-1 following stimulation by CRP and collagen. The tyrosine kinases Lyn, which exists as a 53 and 56-kDa doublet, and Syk were identified as major components of these bands, respectively. Kinase assays on SHP-1 immunoprecipitates performed in the presence of the Src family kinase inhibitor PP1 confirmed the presence of a Src kinase in CRP-but not thrombin-stimulated cells. Lyn, Syk, and SLP-76, along with tyrosinephosphorylated 28-, 32-, and 130-kDa proteins, bound selectively to a glutathione S-transferase protein encoding the SH2 domains of SHP-1, suggesting that this is the major site of interaction. Platelets isolated from motheaten viable mice (mev/mev) revealed the presence of a heavily tyrosine-phosphorylated 26-kDa protein that was not found in wild-type platelets. CRP-stimulated mev/mev platelets manifested hypophosphorylation of Syk and Lyn and reduced P-selectin expression relative to controls. These observations provide evidence of a functional role for SHP-1 in platelet activation by GPVI.
In blood platelets, agonist-induced increases in protein-tyrosine phosphorylation is mediated primarily by cytosolic protein-tyrosine kinases, including members of the Src, Syk, Tec, focal adhesion kinase (FAK), and Jak tyrosine kinases (1, 2) . Indeed, platelets express some of the highest levels of tyrosine kinase activity of any cell in the body, with Syk and Src each making up approximately 0.1-0.2% of cellular protein. Nevertheless, resting platelets have relatively low levels of tyrosinephosphorylated proteins, indicating that protein-tyrosine phosphatase activity must be relatively high (3, 4) . This is illustrated by the dramatic increase of tyrosine phosphorylation observed in platelets within 10 s of incubation with the tyrosine phosphatase inhibitor peroxovanadate (5) . Several proteins undergo only transient increases in tyrosine phosphorylation upon agonist stimulation, e.g. the adapter LAT in response to GPVI 1 activation (6) , further emphasizing the role of protein-tyrosine phosphatases in regulating platelet activation.
The tyrosine phosphatases SHP-1 and SHP-2 both contain tandem SH2 domains within the N-terminus, enabling association with tyrosine-phosphorylated proteins. SHP-1 is restricted to hematopoietic cells, whereas SHP-2 is ubiquitous. SHP-1 has been intensively studied in the regulation of the immune system. Mutation of SHP-1 in mice is accompanied by defects in immunity and hematopoiesis (7) . SHP-1 is selectively recruited to the surface membrane in hematopoietic cells through interaction with a phosphorylated immunoreceptor tyrosine-based inhibitory motif (ITIM) leading to inhibition of immune receptor signaling (8 -10) . For example, recruitment of SHP-1 to CD22, in B-lymphocytes, leads to inhibition of signaling through the B cell antigen receptor (11) (12) (13) . In a similar way, natural killer cells express killer inhibitory receptors that mediate negative regulation of cell cytoxicity via the recruitment of SHP-1 to the phosphorylated ITIM sequence of the killer inhibitory receptor (14, 15) .
In platelets, SHP-1 has been shown to coprecipitate with Src (16) and to bind to an ITIM sequence in the membrane protein PECAM-1 (CD31) following stimulation by thrombin (17, 18) . SHP-2 also associates with PECAM-1 in thrombin-stimulated platelets but with a much greater affinity for the PECAM-1 ITIM sequence compared with SHP-1 (17) (18) (19) . SHP-1 is a substrate for the Ca 2ϩ -dependent protease calpain in platelets, which increases its catalytic activity (20, 21) .
Collagen activates platelets through a tyrosine kinase-based signaling pathway similar to that used by immune receptors. The immunoglobulin collagen receptor GPVI (22) is associated with the FcR ␥-chain which contains one copy of an immunoreceptor tyrosine-based activation motif (ITAM) (23, 24) . Crosslinking of GPVI leads to tyrosine phosphorylation of the FcR ␥-chain ITAM via Fyn and Lyn tyrosine kinases (25, 26) . This leads to recruitment and activation of the tyrosine kinase Syk, initiating a series of events that culminate in phosphorylation and activation of phospholipase C␥2 (27, 28) . Thrombin activation proceeds through a G protein-coupled signaling pathway but also leads to tyrosine phosphorylation of a wide spectrum of proteins through activation of protein kinase C and Ca 2ϩ (29) . The role of tyrosine phosphorylation in thrombin-induced platelet activation is not established.
Despite the fact that collagen and thrombin stimulate a marked increase in tyrosine phosphorylation, the functional role of protein-tyrosine phosphatases in platelet regulation is still poorly understood. In particular, it is not known whether the SHP-1 exerts a selective inhibitory effect on the GPVIregulated ITAM signaling pathway through interaction with an ITIM, analogous to that described in other immune cells. In the present study, we have addressed the role of SHP-1 in platelet activation by the collagen receptor GPVI.
EXPERIMENTAL PROCEDURES
Materials-CRP (GCP*(GPP*) 10 GCP*G, single amino acid code, P* is hydroxyproline), cross-linked through the C-terminal cysteines as described previously (30) , was a kind gift from Drs. Barnes, Knight, and Farndale (Cambridge, United Kingdom). Rabbit anti-SHP-1 polyclonal antibody (C19) was from Santa Cruz (Santa Cruz Biotechnology, Santa Cruz, CA). GST constructs of SHP-1 were generated in the Department of Medicine, Cardiff University.
2 Motheaten (mev/mev) mice were from Jackson laboratory and were maintained under specific pathogen-free conditions within the University of California, San Francisco animal care facility. Animals were provided antibiotic tablets (amoxicillin, 3 mg/tablet, BioServe, Frenchtown, NJ) to prolong survival. Other materials and reagents were from previously described sources (31) .
Preparation of Platelets-Blood was taken from drug-free volunteers on the day of the experiment using acidic citrate dextrose (120 mM sodium citrate, 110 mM glucose, 80 mM citric acid) as anticoagulant. Murine blood was taken by cardiac puncture following carbon dioxide asphyxiation. Platelet-rich plasma was obtained by centrifugation at 200 ϫ g for 20 min. Platelets were isolated by centrifugation at 1,000 ϫ g for 10 min in the presence of prostacyclin (0.1 g/ml) and resuspended in 25 ml of a modified Tyrode-HEPES buffer (31) . Platelets were centrifuged at 1,000 ϫ g for 10 min and resuspended at a concentration of 5 ϫ 10 8 cells/ml in Tyrode-HEPES buffer containing EGTA (1 mM) and indomethacin (10 M). Stimulation was performed in an aggregometer at 37°C under continuous stirring (1,200 rpm) .
Immunoprecipitation Studies-Experiments were stopped by addition of an equal volume of ice-cold lysis buffer (20 mM Tris, 300 mM NaCl, 10 mM EDTA, 2% (v/v) Nonidet P40, 1 mM phenylmethylsulfonyl fluoride, 2 mM Na 3 VO 4 , 10 g/ml leupeptin, 10 g/ml aprotinin, 1 g/ml pepstatin A, pH 7.3). Non-lysed cells and debris were removed by centrifugation and lysates pre-cleared by mixing with protein A-Sepharose for 60 min at 4°C (20 l of a 50% (w/v) suspension of protein A-Sepharose in TBS-T (20 mM Tris, 137 mM NaCl, 0.1% Tween 20, pH 7.3)). SHP-1 was immunoprecipitated from 1 ml of lysate by 5 l of rabbit anti-SHP-1. Following rotation for 60 min, protein A-Sepharose was added and rotation continued for a further 60 min. The pellet of protein A-Sepharose was washed in lysis buffer and three times in TBS-T before the addition of Laemmli buffer (4% SDS, 10% mercaptoethanol, 20% glycerol, 50 mM Tris, pH 6.8).
Fusion Protein Precipitation Studies-The GST fusion proteins containing the tandem SH2 domains, the catalytic domain, and the fulllength protein were expressed and purified using glutathione-agarose. Precipitation of platelet proteins was performed in lysis buffer after pre-clearing of lysates with glutathione-agarose. 5 g of GST fusion protein were used for precipitation with GST as control.
Immunoblotting Studies-Proteins were separated by SDS-polyacrylamide gel electrophoresis and transferred to polyvinylidene difluoride membranes, which had been blocked by incubation in 10% (w/v) bovine serum albumin dissolved in TBS-T. Primary and secondary antibodies were diluted in TBS-T containing 2% (w/v) bovine serum albumin and incubated with membranes for 60 min at room temperature. Blots were washed for 120 min in TBS-T and developed using enhanced chemiluminescence (ECL) detection system. Anti-phosphotyrosine and anti-SHP-1 were used at 1 g/ml and 1:1,000, respectively. Horseradish peroxidase-conjugated secondary antibody was diluted at 1:10,000.
Protein Kinase Assays-Immunoprecipitates were washed as described above and resuspended in 50 l of kinase buffer (20 mM Hepes, 100 mM NaCl, 5 mM MgCl 2 , 5 mM MnCl 2 ). The reaction was started by addition of 5 Ci of [␥-
32 P]ATP and incubated for 10 min at 37°C. The reaction was stopped by adding 1 volume of HCl. The protein A-Sepharose pellet was washed by centrifugation and the supernatant was discarded. Samples were solubilized by addition of 30 l of Laemmli buffer and boiled for 10 min.
Flow Cytometry-Samples (10 6 platelets) in Tyrode-HEPES were incubated with P-selectin antibody and anti-rat fluorescein isothiocyanate-conjugated antibody (5 l each) for 10 min at room temperature. After a 5-fold dilution in Tyrode-HEPES, samples were analyzed using a Becton Dickinson FACScan flow cytometer.
RESULTS

SHP-1 Is Tyrosine Phosphorylated in GPVI-stimulated Plate-
lets-Immunoprecipitation studies reveal that SHP-1 was minimally tyrosine phosphorylated under basal conditions but underwent an increase in phosphorylation on tyrosine in response to the GPVI-selective agonist CRP, collagen, and thrombin. Tyrosine phosphorylation was maximal by 60 s and maintained this level for up to 10 min (data not shown). Major tyrosine phosphorylated proteins of 28 and 32 kDa and a minor band of 130 kDa coprecipitated with SHP-1 under basal conditions and underwent a further increase in phosphorylation in response to stimulation by all three agonists (Fig. 1 ). An additional band migrating at 26 kDa was detected after stimulation in some studies. A broad band of 50 -55 kDa that migrated in the region of the heavy chain and a minor band of 70 kDa were present only in CRP and collagen-stimulated platelets. These bands were shown to contain the tyrosine kinases Lyn, which is present as a doublet, and Syk, respectively, by Western blotting (Fig. 1) . Cross-linking of Fc␥ RIIA, which signals through a similar pathway to GPVI, induced SHP-1 tyrosine phosphorylation and coimmunoprecipitation of a heavily phosphorylated band of 40 kDa, which is the Fc receptor.
In Vitro Kinase Assays on SHP-1 Immunoprecipitates-Kinase assays were performed in vitro on SHP-1 immunoprecipitates to confirm the association with Src and Syk tyrosine 2 Dr. J. R. Matthews, manuscript in preparation. 8 /ml) were incubated with buffer alone (basal), mAb IV.3 (1 g/ml) and F(abЈ)2 anti-mouse IgG (2 g/ml), collagen (Coll, 30 g/ml), CRP (2 g/ml), and thrombin (1 unit/ml) for 2 min at 37°C. The reaction was stopped by addition of ice-cold lysis buffer, and SHP-1 was immunoprecipitated as described under "Experimental Procedures." Samples were Western blotted for anti-phosphotyrosine (i) and then stripped and reblotted for the tyrosine kinase Syk (ii), the tyrosine kinase Lyn (iii), and SHP-1 (iv). Molecular mass markers are indicated on the left. Major tyrosinephosphorylated-associated proteins are indicated on the right. Results shown from one experiment are representative of five.
kinases in CRP-stimulated platelets. SHP-1, along with several other bands, underwent a small increase in phosphorylation in the in vitro kinase assay following immunoprecipitation from non-stimulated platelets (Fig. 2) . In contrast, several proteins underwent large increases in phosphorylation in the kinase assay following stimulation by CRP including SHP-1 itself, an uncharacterized protein of 40 kDa, and a broad band around 50 -55 kDa which comigrates with Lyn. There were smaller increases in phosphorylation of unidentified proteins of 20, 38, 46, 70, and 90 kDa (Fig. 2) . The increase in tyrosine phosphorylation was partially inhibited in the presence of the Src family kinase inhibitor PP1 consistent, with the presence of Lyn in the SHP-1 immunoprecipitate (Fig. 2) . In contrast, there was only a minimal increase in phosphorylation of SHP-1 and a band of 38 kDa in thrombin-stimulated platelets and surprisingly, there was dephosphorylation of several minor bands (Fig. 2) . 2ϩ and Dependent on Src Kinases-To investigate whether a Src family kinase lies upstream of SHP-1 phosphorylation in vivo, platelets were incubated with the specific Src kinase inhibitor PP1 prior to stimulation. PP1 completely inhibited the increase in phosphorylation of SHP-1 observed in response to CRP and markedly reduced the response to thrombin (Fig. 3) . Similar results were obtained in the presence of a second structurally distinct Src family kinase inhibitor PD173956 (data not shown). Interpretation of the result for GPVI, however, is hampered by the critical role of Src family kinases in the phosphorylation of the Fc receptor ␥ chain ITAM, which initiates the signaling cascade (25, 26) . These studies revealed a similar level of tyrosine phosphorylation of SHP-1 in response to CRP and thrombin despite the lack of association of Src and Syk family kinases with the latter. This raises the possibility that tyrosine phosphorylation is mediated by a common mechanism in response to the two agonists and that it may have little functional significance with respect to the role of SHP-1 in the GPVI receptor-signaling cascade. This is supported by the observation that tyrosine phosphorylation of SHP-1 is inhibited by the Ca 2ϩ chelator BAPTA-AM (10 M) in response to thrombin and CRP (Fig. 3) . Additionally, the Ca 2ϩ ionophore, A23187, induces a similar level of tyrosine phosphorylation of SHP-1 to thrombin and CRP, confirming a direct role for the cation in this pathway (data not shown). Tyrosine phosphorylation of SHP-1 therefore appears to be regulated by a common pathway downstream of Ca 2ϩ mobilization.
SHP-1 Tyrosine Phosphorylation Is Downstream of Ca
The Interaction of Tyrosine-phosphorylated Proteins with SHP-1 Is Primarily Mediated through Its SH2 Domains-
The region of SHP-1 that mediates the association with tyrosinephosphorylated proteins in CRP-stimulated platelets was investigated using recombinant GST fusion proteins encoding domains of the phosphatase. GST alone did not associate with tyrosine-phosphorylated proteins in control or stimulated platelets (Fig. 4) . The tandem SH2 domains of SHP-1 (SH2) precipitated several tyrosine phosphorylated proteins from CRP-stimulated platelets, including a broad band of 50 -70 kDa and additional bands of 26, 28, 32, 36, and 130 kDa. The bands of 50 -55 kDa and 70 kDa were also precipitated by full-length SHP-1 (FULL) and by its catalytic domain (CAT), albeit to a lesser extent. A tyrosine-phosphorylated band of 130 kDa associated with full-length SHP-1 was seen in longer exposures from CRP-stimulated platelets.
The proteins precipitated by the various constructs of SHP-1 were probed with antibodies to the tyrosine kinases Syk, Lyn, and SLP-76. Syk was precipitated strongly by the SH2 from CRP-stimulated platelets and to a lesser extent from nonstimulated platelets (Fig. 4) . A lower level of Syk was precipitated by the catalytic domain from CRP-stimulated platelets. This raises the possibility that Syk is a substrate for SHP-1, accounting for the weaker association with full-length SHP-1 relative to the tandem SH2 domains. The tyrosine kinase Lyn was precipitated from CRP-stimulated platelets by all three fusion proteins. The adaptor molecule, SLP-76, was constitutively precipitated by the tandem SH2 domain of SHP-1 whereas a CRP-stimulated dependent association was seen with the full-length SHP-1. As for Syk, the apparently weak association of Lyn with the catalytic domain may be because of phosphatase activity. This is supported by the increased level of association of both proteins with the catalytic domain after inactivation of the phosphatase group with an oxidizing agent (data not shown). Syk and Lyn therefore associate with the /ml) were incubated with buffer alone (basal), CRP (2 g/ml), and thrombin (thr, 1 unit/ml) for 2 min at 37°C. The reaction was stopped by addition of ice-cold lysis buffer, and samples were treated as in Fig. 1 . After washing, SHP-1 immunoprecipitates were resuspended in kinase buffer, the reaction was started by addition of 10 Ci tandem SH2 domains and catalytic regions of the phosphatase (Fig. 4) .
Inhibition of CRP-stimulated Responses in mev/mev Platelets-To investigate the role of SHP-1 in platelets, we performed studies on cells from mev/mev mice, which contain a mutation within the shp-1 gene that results in nearly complete loss of catalytic activity (7) . Only a limited amount of tissue could be obtained from these mice, which die within a few weeks after birth. Moreover, the oldest animals were thrombocytopenic, which severely restricted the studies that could be performed (platelet number, 0.6 ϫ 10 8 /ml Ϯ 0.2, n ϭ 5 versus 3.2 ϫ 10 8 /ml Ϯ 0.7, n ϭ 5 for controls). Measurement of whole cell tyrosine phosphorylation in platelet lysates revealed the presence of a major tyrosine-phosphorylated protein of 26 kDa in non-stimulated mev/mev platelets which was absent in control cells (Fig. 5) . The 26-kDa protein migrates below the heavily phosphorylated 28-and 32-kDa proteins that bind to the tandem SH2 domains of SHP-1. The level of tyrosine phosphorylation of other bands in non-stimulated mev/mev platelets was similar to that in controls. A weak reduction in whole cell tyrosine phosphorylation was seen in response to CRP in the mev/mev platelets relative to controls (Fig. 5) . This was particularly striking for a broad 70-kDa band, which has been previously shown to contain Syk, SLP-76, and Btk.
To investigate the effect of the mutant form of SHP-1 on the regulation of Lyn and Syk by CRP, these proteins were immunoprecipitated from control and stimulated platelets. Basal tyrosine phosphorylation of Lyn was similar in control and mev/mev mice platelets (Fig. 5) . As previously reported (26) , stimulation by CRP had little effect on the level of tyrosine phosphorylation of Lyn in wild-type platelets, whereas in mev/ mev platelets, there was a decrease in phosphorylation at 30 s that was maintained for up to 120 s (Fig. 5) . Minimal phosphorylation of Syk was observed under basal conditions in both groups of platelets. However, the increase in tyrosine phosphorylation of Syk in CRP-stimulated platelets was reduced in mev/mev platelets relative to controls, most notably at early times of stimulation (Fig. 5) .
We monitored the expression of P-selectin, a marker of ␣-granule secretion, in response to CRP in control and mev/ FIG. 4 . The tandem SH2 domains of SHP-1 bind to tyrosinephosphorylated proteins in human platelets. Platelets (5 ϫ 10 8 / ml) were stimulated with buffer alone or CRP (2 g/ml) for 2 min at 37°C. Reactions were stopped by addition of ice-cold lysis buffer and samples were pre-cleared with glutathione-Sepharose and then incubated with the indicated GST fusion proteins for 4 h. After electrophoresis and transfer, membranes were blotted for tyrosine phosphorylation (i), the tyrosine kinases Syk (ii), Lyn (iii), and the adaptor SLP-76 (iv). ii, platelets were stimulated by 2 g/ml CRP for 30 and 120 s. The reaction was stopped by addition of ice-cold lysis buffer and Lyn (a) and Syk (b) were immunoprecipitated. The membrane was probed for antiphosphotyrosine (␣ p-Tyr, upper panels of a and b) and reprobed for Lyn and Syk, respectively (lower panels of a and b). Results shown from one experiment are representative of five. iii, platelets from control and mev/mev mice were stimulated by the indicated concentration of CRP for 2 min at 37°C. An aliquot (10 6 cells) was incubated with anti-Pselectin antibody and a fluorescein isothiocyanate-conjugated anti-rat antibody (5 l each) for 10 min. After a 5-fold dilution, samples were analyzed by flow cytometry. Results were analyzed as a dot-plot. Results are presented as mean Ϯ S.E. (bars) of three experiments. mev platelets. The basal level of expression of P-selectin was not altered in mev/mev and control mice. However, expression of P-selectin in response to 1 g/ml CRP was strongly reduced in mev/mev mice, and the response to a supramaximal concentration of CRP (10 g/ml) was reduced by 50% relative to control platelets (Fig. 5) .
DISCUSSION
The present study was undertaken to investigate the role of the SH2 domain-containing protein-tyrosine phosphatase, SHP-1, in GPVI signaling in platelets. SHP-1 is rapidly tyrosine phosphorylated in response to the collagen-related peptide, CRP, through a pathway that is regulated by Ca 2ϩ . Stimulation leads to the in vivo association of SHP-1 with a number of tyrosine-phosphorylated bands, including two major uncharacterized bands of 28 and 32 kDa and further bands of 50 -55, 70, and 130 kDa. The tyrosine kinases Lyn and Syk, which play critical roles in the GPVI signaling pathway, were identified as components of the 50 -55-and 70-kDa bands, respectively. The major site of interaction of Syk, SLP-76, and Lyn with SHP-1 is through the tandem SH2 domains of the phosphatase, although both Syk and Lyn kinases also bind to the catalytic domain. Inactivation of the catalytic domain of SHP-1 through oxidation led to an increase in association with the tyrosine kinases Lyn and Syk raising the possibility that Syk and Lyn are substrates for SHP-1 in vivo. Studies on mev/mev platelets were unable to establish, however, whether this is the case because of the general inhibition of response to GPVI. It is not known whether the interaction of Syk and Lyn with the tandem SH2 domains of SHP-1 is direct or via an intermediatory protein. A constitutive association of SLP-76 with SHP-1 via its N-terminal SH2 domain has been reported in B cells (32) . We found a similar constitutive association in vitro in platelets, although no in vivo association with SHP-1 was detected. In T and natural killer cells, SLP-76 has been detected by farwestern using a non-active catalytic domain of SHP-1, suggesting it is a substrate of the phosphatase (33) . We were unable to show such association in vitro using the catalytic domain of SHP-1 in precipitation assay in platelets.
SHP-1 is also phosphorylated in response to the G proteincoupled receptor agonist thrombin through a pathway that is also regulated by Ca 2ϩ . Similarly, thrombin induces association of SHP-1 with proteins of 28, 32, and 130 kDa, although there is no interaction with Lyn and Syk. It appears that mobilization of Ca 2ϩ mediates SHP-1 phosphorylation in platelets by multiple agonists, whereas association with Lyn and Syk is specific to the GPVI signaling pathway.
A number of uncharacterized, tyrosine-phosphorylated proteins were observed to associate with SHP-1 in platelets. This includes two prominent bands of 28 and 32 kDa, which are present at low level in SHP-1 immunoprecipitates in resting cells and at high levels in CRP-stimulated samples and a 130-kDa protein, which is clearly seen in stimulated cells. A similar pattern of interaction of tyrosine-phosphorylated proteins has been reported in SHP-2 immunoprecipitates in platelets stimulated by thrombin (19) . The interaction of these three phosphorylated proteins with SHP-1 is mediated solely through the SH2 domains of the phosphatase making it extremely unlikely that they are substrates. Their ability to associate with the tandem SH2 domains of SHP-1 suggests that they may help to localize the phosphatase to key regions in the cell. It is therefore of considerable interest to establish whether one or more of these proteins are transmembrane and whether they possess ITIMs. The 130-kDa protein migrates in the same region as PECAM-1, which contains an ITIM sequence and is expressed in platelets (17); however, we were unable to identify PECAM-1 as a component of this band in vivo through immunoblotting or re-immunoprecipitation combined with blotting for phosphotyrosine. Yang et al. (34) reported association of a 32-kDa band with SHP-1, but the interaction was through the C terminus suggesting that it is unrelated to the 28-and 32-kDa proteins observed in this study (34) .
The functional significance of SHP-1 in GPVI receptor signaling was investigated in platelets derived from mev/mev mice. An uncharacterized 26-kDa protein was heavily tyrosine phosphorylated in mev/mev platelets, and the increase in tyrosine phosphorylation in whole cell lysates in response to CRP was reduced. There was a reduction in phosphorylation of the tyrosine kinase Syk and expression of P-selectin, a marker of ␣-granule secretion, in response to CRP. Additionally, the tyrosine kinase Lyn was dephosphorylated in mev/mev platelets in response to CRP suggesting that another phosphatase underlies this dephosphorylation. The absence of active SHP-1 therefore exerts an inhibitory effect on GPVI receptor signaling, rather than causing potentiation as observed in other immune cells. The reduction in phosphorylation of Lyn may be a contributing factor to the inhibition of response to CRP through loss of phosphorylation of the FcR ␥-chain ITAM (25, 26) . Studies on me/me mice, which do not express SHP-1, may shed further light on the role of the phosphatase in platelets.
There is considerable interest in the identity of the tyrosinephosphorylated 26-kDa protein, which is present in mev/mev platelets. This protein migrates below p28 and p32 and therefore appears to be distinct. Because the presence of this protein is unmasked in the absence of active SHP-1, it is possible that it is a substrate for the phosphatase. This contrasts with the p28 and p32 bands which are unlikely to be substrates for the reasons discussed above. In view of the fact that the absence of active SHP-1 reduces platelet activation to GPVI, it is important to establish whether this is brought about by the increase in phosphorylation of p26. If this is the case, the possibility that p26 has an ITIM group and is membrane localized is deserving of close attention.
The functional significance of the present observations is unclear. In the majority of other hematopoietic cells, SHP-1 has been shown to exert an inhibitory influence on ITAM-dependent activation through its ability to bind to ITIMs and mediate dephosphorylation of key proteins in the activation cascade. It is possible that SHP-1 plays a similar role in platelets, possibly through recruitment to the 28-, 32-and 130-kDa proteins identified in this study, with Syk and Lyn serving as potential substrates. This may help to prevent unwanted platelet activation at key sites in the vasculature. However, platelets from motheaten viable mice are hyporesponsive to GPVI stimulation, suggesting a physiological role for SHP-1 in lowering the threshold for activation by GPVI. This will help to facilitate rapid platelet activation at sites of damage to the vasculature.
